PASSReviewer 1· 85% conf
The paper is transparent about methods, limitations, and funding, and reports all outcomes, though it does not reference a specific reporting guideline.
Evidence
paraphrase[Funding]
“DECLARE-TIMI 58 ( NCT01730534 ) was funded by AstraZeneca.”paraphrase[Discussion, paragraph 5]
“These findings must be interpreted in the context of our study design. Although this randomized dataset enabled evaluation of the interaction between rare CMP variant carrier status and SGLT2 inhibitor therapy, the relatively small number of carriers ( n = 121) limits power for subgroup analyses...”paraphrase[Funding and Competing interests]
“DECLARE-TIMI 58 ( NCT01730534 ) was funded by AstraZeneca.”PASSReviewer 2· 85% conf
The paper is transparent about methods, limitations, and funding, and reports all outcomes. However, it does not reference a specific reporting guideline or provide a trial registration number for this secondary analysis.
Evidence
direct quote[Discussion, paragraph 5]
“These findings must be interpreted in the context of our study design. Although this randomized dataset enabled evaluation of the interaction between rare CMP variant carrier status and SGLT2 inhibitor therapy, the relatively small number of carriers ( n = 121) limits power for subgroup analyses”paraphrase[Funding and Competing interests]
“DECLARE-TIMI 58 ( NCT01730534 ) was funded by AstraZeneca.”absence[Methods]
No reporting guideline is referenced.